233 related articles for article (PubMed ID: 21641678)
21. Colistin: new lessons on an old antibiotic.
Yahav D; Farbman L; Leibovici L; Paul M
Clin Microbiol Infect; 2012 Jan; 18(1):18-29. PubMed ID: 22168320
[TBL] [Abstract][Full Text] [Related]
22. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria.
Rattanaumpawan P; Lorsutthitham J; Ungprasert P; Angkasekwinai N; Thamlikitkul V
J Antimicrob Chemother; 2010 Dec; 65(12):2645-9. PubMed ID: 20876621
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections.
Falagas ME; Rafailidis PI; Kasiakou SK; Hatzopoulou P; Michalopoulos A
Clin Microbiol Infect; 2006 Dec; 12(12):1227-30. PubMed ID: 17121631
[TBL] [Abstract][Full Text] [Related]
24. A closer look at aerosolized colistin.
van Leeuwen DH
Clin Infect Dis; 2011 Jun; 52(12):1472-3; author reply 1473-4. PubMed ID: 21628491
[No Abstract] [Full Text] [Related]
25. [Clinical assessment of colistin in treating infections caused by multidrug-resistant gram-negative bacillus in patients with severe burn].
Zhang JP; Yang XS; Chen J; Peng YZ; Huang YS
Zhonghua Shao Shang Za Zhi; 2009 Oct; 25(5):372-6. PubMed ID: 19951562
[TBL] [Abstract][Full Text] [Related]
26. Inhaled antibiotic therapy for ventilator-associated tracheobronchitis and ventilator-associated pneumonia: an update.
Abu-Salah T; Dhand R
Adv Ther; 2011 Sep; 28(9):728-47. PubMed ID: 21833701
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
Li J; Nation RL; Milne RW; Turnidge JD; Coulthard K
Int J Antimicrob Agents; 2005 Jan; 25(1):11-25. PubMed ID: 15620821
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic evaluation of colistin sodium.
Michalopoulos AS; Karatza DC; Gregorakos L
Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):245-55. PubMed ID: 21128824
[TBL] [Abstract][Full Text] [Related]
29. Colistin and polymyxin B in critical care.
Michalopoulos A; Falagas ME
Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952
[TBL] [Abstract][Full Text] [Related]
30. [Shedding light on the use of colistin: still gaps to be filled].
Luque S; Grau S; Berenguer N; Horcajada JP; Sorlí L; Montero MM; Salas E
Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):287-96. PubMed ID: 21440335
[TBL] [Abstract][Full Text] [Related]
31. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09).
Gales AC; Jones RN; Sader HS
J Antimicrob Chemother; 2011 Sep; 66(9):2070-4. PubMed ID: 21715434
[TBL] [Abstract][Full Text] [Related]
32. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
Paul M; Daikos GL; Durante-Mangoni E; Yahav D; Carmeli Y; Benattar YD; Skiada A; Andini R; Eliakim-Raz N; Nutman A; Zusman O; Antoniadou A; Pafundi PC; Adler A; Dickstein Y; Pavleas I; Zampino R; Daitch V; Bitterman R; Zayyad H; Koppel F; Levi I; Babich T; Friberg LE; Mouton JW; Theuretzbacher U; Leibovici L
Lancet Infect Dis; 2018 Apr; 18(4):391-400. PubMed ID: 29456043
[TBL] [Abstract][Full Text] [Related]
33. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.
Falagas ME; Kasiakou SK
Clin Infect Dis; 2005 May; 40(9):1333-41. PubMed ID: 15825037
[TBL] [Abstract][Full Text] [Related]
34. Polymyxin B: similarities to and differences from colistin (polymyxin E).
Kwa A; Kasiakou SK; Tam VH; Falagas ME
Expert Rev Anti Infect Ther; 2007 Oct; 5(5):811-21. PubMed ID: 17914915
[TBL] [Abstract][Full Text] [Related]
35. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia.
Vicari G; Bauer SR; Neuner EA; Lam SW
Clin Infect Dis; 2013 Feb; 56(3):398-404. PubMed ID: 23090926
[TBL] [Abstract][Full Text] [Related]
36. Intravenous combined with aerosolised polymyxin versus intravenous polymyxin alone in the treatment of pneumonia caused by multidrug-resistant pathogens: a systematic review and meta-analysis.
Liu D; Zhang J; Liu HX; Zhu YG; Qu JM
Int J Antimicrob Agents; 2015 Dec; 46(6):603-9. PubMed ID: 26607337
[TBL] [Abstract][Full Text] [Related]
37. Colistin pharmacokinetics: the fog is lifting.
Couet W; Grégoire N; Marchand S; Mimoz O
Clin Microbiol Infect; 2012 Jan; 18(1):30-9. PubMed ID: 21988234
[TBL] [Abstract][Full Text] [Related]
38. Continuous versus intermittent infusion of polymyxin B in the treatment of infections caused by multidrug-resistant Gram-negative bacteria.
Teng CB; Koh PT; Lye DC; Ang BS
Int J Antimicrob Agents; 2008 Jan; 31(1):80-2. PubMed ID: 17920246
[No Abstract] [Full Text] [Related]
39. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study.
Korbila IP; Michalopoulos A; Rafailidis PI; Nikita D; Samonis G; Falagas ME
Clin Microbiol Infect; 2010 Aug; 16(8):1230-6. PubMed ID: 19732088
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria.
Falagas ME; Kasiakou SK; Kofteridis DP; Roditakis G; Samonis G
Eur J Clin Microbiol Infect Dis; 2006 Sep; 25(9):596-9. PubMed ID: 16955249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
